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Consumer reviewsCSIRO Adverse Drug Event Corpus (CADEC) is a new rich annotated corpus of medical forum posts on
patient-reported Adverse Drug Events (ADEs). The corpus is sourced from posts on social media, and con-
tains text that is largely written in colloquial language and often deviates from formal English grammar
and punctuation rules. Annotations contain mentions of concepts such as drugs, adverse effects, symp-
toms, and diseases linked to their corresponding concepts in controlled vocabularies, i.e., SNOMED
Clinical Terms and MedDRA. The quality of the annotations is ensured by annotation guidelines, multi-
stage annotations, measuring inter-annotator agreement, and ﬁnal review of the annotations by a clinical
terminologist. This corpus is useful for studies in the area of information extraction, or more generally
text mining, from social media to detect possible adverse drug reactions from direct patient reports.
The corpus is publicly available at https://data.csiro.au.1
 2015 Elsevier Inc. All rights reserved.1. Introduction
Due to limitations in clinical trials, not all the potential side
effects of medications are discovered prior to the drug going to
market [3]. Adverse drug reactions that remain unknown create
major concerns in public health [7]. They are responsible for thou-
sands of incidents of death or serious injury, as well as millions of
hospitalisations. Consequently, they cost billions of dollars to the
healthcare systems around the world [1,14,27].
Postmarket surveillance, also known as pharmacovigilance,
plays an important role in identifying those adverse drug side
effects that are left undetected while a drug is in the market
[3,6]. The traditional surveillance practice, enforced by regulatory
agencies such as the Food and Drug Administration (FDA) in the
US and the Therapeutic Goods Administration (TGA) in Australia,
is to collect volunteer reports of adverse drug side effects, investi-
gate the reports, and issue safety signals if a drug is suspected to
cause an adverse effect.
More recently, active surveillance has been studied where dif-
ferent data sources are automatically monitored for reports of pos-
sible adverse reactions; FDA’s Sentinel Initiative is an example of
active monitoring. One of the information sources that could beactively monitored is medical forums where consumers discuss
their ﬁrst-hand experience with medications.
A human annotated corpus is a valuable resource in the develop-
ment and evaluation of text-mining methods reliant on machine
learning. Such annotations need to account for medications and
adverse effects, as well as patient condition and demographic data.
Such a corpus can be expensive to construct but once created will
servemultiple studies in the advancement of their text-mining algo-
rithms. Therefore, we developed a corpus of medical forum posts
taken from AskaPatient2 which collects ratings and reviews of med-
ications fromtheir consumers. Thesepostswere annotated for entities
such as the names of the drugs consumed, and their adverse effects.
Additionally, these annotated entities were linked to controlled
vocabularies: the Systematized Nomenclature of Medicine Clinical
Terms (SNOMED CT), AMT (The Australian Medicines Terminology)
and MedDRA (The Medical Dictionary for Regulatory Activities).
To our knowledge, our corpus is the ﬁrst richly annotated and
publicly available corpus ofmedical forum posts that can be applied
to text mining tasks related to pharmacovigilance.
2. Related work
We review the existing relevant corpora and their speciﬁcations,
as well as a brief overview of methodologies proposed in the litera-
ture to extract drug adverse effect information from social media.
3 SemEval (Semantic Evaluation) is a shared task for evaluations of semantic
analysis systems on a shared dataset and agreed evaluation metrics.
4 www.dailystrength.org.
5 Coding Symbols for a Thesaurus of Adverse Reaction Terms (COSTART) was
developed by the FDA for coding of adverse drug reaction in post-market reports. It is
now replaced by MedDRA.
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Literature reports on the corpora that are annotated to facilitate
information extraction from biomedical literature, electronic
health records, and other textual data. Below, we introduce some
of these corpora together with their speciﬁcations such as anno-
tated entities and their data sources, as well as stating the differ-
ences to our corpus. We only review those datasets that share
either an entity of interest with our corpus, or are closely related
to text mining in the pharmacovigilance area.
Leaman et al. [17] developed the Arizona Disease Corpus (AZDC)
where biomedical literature (MEDLINE abstracts) were annotated for
mentions of diseases. The disease mentions were then normalised
to their corresponding UMLS concepts. They also demonstrated
that disease mentions have similar characteristics to entities such
as genes and proteins. That is, they have name variants, one name
can refer to entities of different semantic types, and are prone to
complex syntactic structures. These characteristics can lead to
ambiguity in automatically recognising disease mentions in text.
In 2014, an extension of AZDC called the NCBI disease corpus [9]
was introduced which annotates disease mentions in PubMed
abstracts using a web-based tool called PubTator [31]. These men-
tions were then linked to Medical Subject Headings (MeSH) or
Online Mendelian Inheritance in Man (OMIM) standard terminolo-
gies. The annotations were done by 14 annotators each annotating
four to ﬁve batches of 30 abstracts with each batch receiving at
least two annotations. Annotators were given detailed guidelines.
Roberts et al. [26] annotated deceased cancer patient records
for a large number of entities such as intervention, drug or device,
and condition (full list in Table 1, second row). Their data, which
was used in a shared task, was created based on carefully designed
guidelines ﬁnalised after an initial set of annotations. They hired 25
annotators, and had each document annotated twice in order to
calculate inter-annotator agreement. Their deﬁnition of entities
was generally inclusive and inspired from the UMLS concepts.
For example, they annotated drugs and medical devices under
the same entity. Their condition entity type also covered a range
of concepts such as symptoms, complications, and injuries.
Gurulingappa et al. [10] described a corpus of annotated MEDLINE
abstracts for human diseases and adverse effects. The abstracts
were found by querying PubMed for ‘‘disease OR adverse effect’’
and then a subset of 400 abstracts was randomly chosen to be
annotated. Two annotators were instructed to identify mentions
of disease and adverse effects based on their context. The ﬁnal cor-
pus contains 813 mentions of adverse effects and 1428 mentions of
disease. The corpus is publicly available with the annotations in
the IOB (Inside, Outside, Beginning) format.
Gurulingappa et al. [11] created a corpus for extracting informa-
tion related to drug safety from medical case reports in MEDLINE. The
MEDLINE abstracts were chosen randomly from the pool of abstracts
returned by querying PubMed with the MeSH (Medical Subject
Headings) terms ‘‘drug therapy’’ and ‘‘adverse effect’’. The corpus
was annotated by three annotators for the mentions of drugs
(brand names, trivial names, abbreviations), adverse effects,
dosage (quantity and frequency), as well as the relationships
among these entities. Adverse effects of a certain drug covered a
range of signs, symptoms, diseases, disorders, abnormalities, organ
damage and even death caused by that drug.
In their annotations, Gurulingappa et al. [11] excluded names of
medical devices or hospital chemicals. Also, they only annotated
drug name mentions in relation to an adverse event. The ﬁnal cor-
pus included those sentences from the abstracts that had at least
one mention of an adverse effect.
Van Mulligen et al. [30] report a publicly available annotated
corpus of biomedical literature where instances of drugs, disorders,
genes, and the relationships among the identiﬁed entities areannotated. Data for the corpus was collected by querying
PubMed. Search strategies are listed in their paper. They initially
annotated the corpus using a Named Entity Recogniser (NER) and
then asked their annotators to correct the automatic annotations.
Deleger et al. [8] created an annotated corpus of clinical records.
The corpus was created with two different purposes: (1) a de-iden-
tiﬁcation task for which the data was annotated for personal health
information such as patient’s age or email address; and (2) annota-
tion of entities related to the medication, such as medication name
and type, as well as disease and symptoms. Annotations in this
step were based on SNOMED CT and UMLS concepts. Annotators
were instructed to annotate entities if there existed a correspond-
ing SNOMED CT or UMLS concept. Deleger et al. [8] annotated a
corpus of clinical notes and the FDA drug labels using two annota-
tors. A guideline was developed and updated after a trial annota-
tion step. They calculated inter-annotator agreement to ensure
only documents with full agreement were included in the ﬁnal
corpus.
One line of work in the area of pharmacovigilance is studying
the drug-drug interactions (DDIs) that lead to adverse drug reac-
tions. Herrero-Zazo et al. [13] created a corpus that supports
text-mining in this area. Data for the corpus was sourced from
DrugBank [32] and MEDLINE abstracts. Annotations followed care-
fully written guidelines by two pharmacists. The data was initially
annotated by MetaMap to identify mentions of biomedical entities
and then passed to the annotators for further curation and correc-
tion. Inter-annotator agreements are reported separately for the
entities and relationships. This corpus has been used in the
SemEval3 2013 shared task. Our corpus is different as it does not
look at the drug-drug interactions and instead focuses on reported
adverse effects of a single drug.
We summarise the existing corpora in Table 1. The second col-
umn speciﬁes the origin of the dataset. The type of data and the
corpus size are listed in the third and forth columns. The annotated
entities and relationships among these entities are listed in the
ﬁnal column of the table. Note that often the same entity type,
for example drug, differs in its deﬁnitions across different corpora.
All the existing corpora are created on the basis of biomedical
literature, e.g., from MEDLINE abstracts. The CADEC corpus, which we
introduce further in the following sections, is the only corpus that
is sourced from consumer reports on social media, introducing its
unique linguistic characteristics and processing challenges.2.2. Drug adverse effect mining from social media
Mining signals of adverse drug reactions from social media has
been studied since 2010. Leaman et al. [18] mined patients’ com-
ments on a medical forum called DailyStrength4 to ﬁnd mentions
of adverse drug events. Their data was annotated for adverse effect,
beneﬁcial effect, indication, and other. They used a lexicon that com-
bines COSTART5 and a few other resources to extract adverse effect
information from patient comments using a sliding window
approach.
Chee et al. [4] applied classiﬁers to identify drugs that have
potential for becoming part of the watchlist of the FDA. They used
patients posts on Health and Wellness Yahoo! Groups.
Benton et al. [2] extracted potential adverse effects from a num-
ber of different breast cancer forums, such as breastcancer.org,
using frequency counts of terms in a controlled vocabulary. They
Table 1
Speciﬁcations of the existing relevant corpora and CADEC.
Corpus Origin Type Size Entities/relationships
Leaman et al.
[17]
MEDLINE Literature 749 abstracts (2784 sentences) Disease
Roberts et al.
[26]
Royal Marsden
Hospital
Cancer patient records 150 documents (50 clinical
narratives, 50 histopathology
reports, 50 imaging reports)
Condition, intervention, investigation, result, drug or device,
locus, negation signal, laterality signal, sub-location signal, and
relations
Gurulingappa
et al. [10]
MEDLINE Literature 400 abstracts Disease, adverse effect
Gurulingappa
et al. [11]
MEDLINE Medical case reports 2972 abstracts (4272 sentences) Drug, adverse effect, dosage, relationships among these entities
Deleger et al.
[8]
Cincinnati children’s
hospital,
ClinicalTrials.gov,
DailyMed
FDA drug labels,
clinical trial
announcements,
clinical notes
3503 clinical notes for personal
health information, 1655 for
disease and disorder
Medication name, medication type, date, dosage, duration, form,
frequency, route, status change, strength, modiﬁer, disease/
disorder, sign/symptom, and personal health information (age,
date, email, etc.)
Van Mulligen
et al. [30]
MEDLINE Literature 300 abstracts Drug, disorder, gene, relationships among these entities
Herrero-Zazo
et al. [13]
MEDLINE and DrugBank
database
Literature and drug
information
233 MEDLINE abstracts and 792
text from DrugBank
Pharmacological substance (drug generic name, brand, drug
group, and active substances not approved for human use), four
types of DDI relationships
Dogan et al.
[9]
PubMed abstracts Literature 793 abstracts (6881 sentences) Disease mentions
Our corpus
(CADEC)
AskaPatient Medical forum 1253 posts (7398 sentences) Drug, adverse effect, disease, symptom, ﬁnding
S. Karimi et al. / Journal of Biomedical Informatics 55 (2015) 73–81 75then used association rule mining to establish the relationship
between the matching terms. Association rule mining is a
data-mining approach popular for mining adverse effects from
regulatory and administrative databases. Yang et al. [33] studied
signal detection from a medical forum called MedHelp6 by
extending the existing association rule mining algorithms by adding
interestingness and impressiveness metrics. To ﬁnd mentions of
adverse drug effects in the text, they used a sliding window and a
consumer controlled vocabulary to match the terms.
Liu and Chen [21] implemented a system called AZDrugMiner.
Data was collected using a crawler from Diabetes Online
Community.7 To ﬁnd mentions of adverse effects and related infor-
mation or relationships such as drug-adverse effect, they ﬁrst used
MetaMap which maps text to UMLS concepts, and then extracted
relations using co-occurrence analysis.
A full review of these techniques can be found in [16]. All of
these studies are evaluated on different privately held corpora,
which makes the comparison of their effectiveness difﬁcult. The
provision of a public corpus such as CADEC will facilitate the com-
parison and evaluation of these mining techniques.3. Corpus material
The data for the CADEC corpus was sourced from a medical forum
calledAskaPatient,which is dedicated to consumer reviews onmed-
ications. Patients can rate the medication by ﬁlling a detailed form
on a speciﬁc drug based on their brand name, e.g., Tamiﬂu. This form
requests satisfaction rate, reason for taking the drug, dosage and
frequency, duration of taking the drug, side effects experienced in
free-text form, comments in free text form, as well patient
demographics including age and gender. Not all the information in
the rating form is mandatory. Also, there is a one review per drug
policy in thewebsitewhere consumers are asked not to entermulti-
ple reviews unless they want to update their previous post.
AskaPatient provided us with consumer posts on the following
12 drugs: Voltaren (Diclofenac Sodium), Cataﬂam (Diclofenac
Potassium), Voltaren-XR (Diclofenac Sodium), Arthrotec
(Diclofenac Sodium; Misoprostol), Pennsaid (Diclofenac Sodium),
Solaraze (Diclofenac Sodium), Flector (Diclofenac Epolamine),6 www.medhelp.org/.
7 http://community.diabetes.org.Cambia (Diclofenac Potassium), Zipsor (Diclofenac Potassium),
Diclofenac Sodium, Diclofenac Potassium, and Lipitor (Atorvastatin
Calcium). We divided these medications into two categories:
Diclofenac, which includes those medications with Diclofenac in
their active ingredient, and Lipitor. As per the rating form explained
above, these posts contain patient demographics, a satisfaction rat-
ing on the medication from 1 (low) to 5 (high), reason for taking the
medication, how it was administered, patient comments on the
effectiveness of the drug and if any side effects were experienced.
A sample post for Voltaren is shown in Table 2. In CADEC, we only
annotate and provide the free text sections of each post. The lan-
guage of all these posts is English. Most of the posts are written in
colloquial language and do not follow formal English grammar and
punctuation rules. They largely report the patients personal experi-
ence, however, sometimes conditions of a family member were
reported.
Statistics on the posts that are used to create the corpus are
shown in Table 3. Statistics are listed for the entire corpus, as well
as each drug category (Diclofenac and Lipitor) separately. Number
of posts for the original data was 1321, however, 71 posts did not
contain any text. These posts were excluded from the ﬁnal corpus.
The length of the posts and their average size in sentences and
words are also reported in Table 3, rows four to seven. Lipitor
has a substantially higher number of posts in a similar time span
than Diclofenac with each post being longer on average. Gender
of the reporting consumers are almost equally divided between
men and women, with 42 posts missing gender information. Age
range of the patients was from 17 to 84 years old, with average
age being 52.
4. Annotation
We annotated the corpus in two main stages: (1) entity iden-
tiﬁcation, and (2) terminology association, also known as normal-
isation, to link the identiﬁed entities to controlled vocabularies.
Below we explain the annotation guidelines, the tools used dur-
ing the annotation, and the annotation process.
4.1. Guidelines
Annotation guidelines are a method of controlling the quality of
the corpus construction, with a number of suggestions provided in
Table 2
A sample post on Voltaren in AskaPatient.com.
Rating Reason Side effects Comments Sex Age Duration/dosage Date
added
4 Osteoarthritis
of the hip
It helps relieve chronic pain but over time, causes
intestinal pain and bleeding. I had symptoms
similar to diverticulitis: blood in stool, pain
I would be cautious about paying attention
to cramping, intestinal/stomach pain which
can lead to very serious conditions
M 63 1.5 years
100MG ER 1X D
4/12/
2013
Table 3
Statistics on the data used in CADEC.
Corpus Diclofenac Lipitor
No. posts 1321 264 1057
No. posts with
text
1250 250 1000
No. sentences 7632 1263 6369
Avg. post
length
(sentence)
6 5 6
No. words 101,486 16,778 84,708
Avg. post
length
(word)
81 67 85
Time span January 2001–
September
2013
February
2002–August
2013
January 2001–
September
2013
Gender F 662 (50.1%) F 181 (68.6%) F 481 (45.6%)
M 617 (49.9%) M 76 (28.8%) M 541 (51.2%)
Age range 17–84 17–78 19–84
Avg. age 52 47 54
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We adapted some of the suggestions by Zazo et al. [12] in creating
the guidelines. Annotations were done at the sentence level. No
entity that spanned over sentences was annotated. Annotations
could be discontinuous within the same sentence. Duplicate enti-
ties within one sentence were annotated independently, that is,
all the occurrences of the same entity were annotated. Generic
mentions of an entity were not annotated, for example, the term
side effect. Embedded entities were not separately annotated.
That is, if part of an entity contained another entity, only the main
entity was annotated. For example, if the post mentions muscle
pain as an adverse side effect, pain is not separately annotated as
another entity. Co-referential/anaphoric references were not anno-
tated. Leading prepositions, qualiﬁers, or possessive adjectives
were excluded to promote more consistent spans. For example,
arthritis was annotated instead of my arthritis.
Speciﬁcally, for the ﬁrst stage of the annotations we deﬁned the
entities of interest as below. These entities and their deﬁnitions
were modiﬁcations of entities proposed by Karimi et al. [15].
Drug Mentions of the name of a medicine or drug are anno-
tated with drug. Drug classes, such as Nonsteroidal
anti-inﬂammatory drugs (NSAIDS), were excluded.
Medical devices were also excluded. For example, in
the sentence ‘‘I must be addicted to Diclofenac’’,
‘‘Diclofenac’’ is annotated with Drug.
ADR Mentions of adverse drug reactions that, according to
the text, are clearly associated with a drug are anno-
tated with an ADR label. For example, in the sentence
‘‘Sometimes causes drowsiness.’’, ‘‘drowsiness’’ is an
adverse effect. All the necessary context for an ADR
concept is annotated. For example, if the sentence said
‘‘I experience acute stomach pain. . .’’, then ‘‘acute
stomach pain’’ is annotated not just ‘‘stomach pain’’,
whereas in a sentence such as ‘‘I felt blank like a blank
piece of paper’’, only ‘‘felt blank’’ is annotated.Disease This entity speciﬁes the reason for taking the drug.
Patients may mention the name of a disease for which
they take the medicine. If it is a speciﬁc disease name,
it is tagged with Disease. For example, in the sentence
‘‘. . .after 3 years of having Ativan keep the anxiety &
aggression in check. . .’’, both ‘‘anxiety’’ and ‘‘aggres-
sion’’ are annotated (separately) as Disease.
Symptom This entity speciﬁes a reason for taking the drug.
Patients may mention symptoms of a disease that led
to them taking a drug. For example, in the sentence,
‘‘My heart was racing and . . .’’, a symptom ‘‘heart rac-
ing’’ is highlighted.
Finding A clinical ﬁnding is any adverse side effect, disease or
symptom that was not directly experienced by the
reporting patient, or any other clinical concept that
could fall in any of these categories but the annotator
is not clear as to which one it belongs.
These deﬁnitions were ﬁnalised after receiving feedback from
the annotators and experts in the ﬁeld, including a pharmacist. A
pilot annotation task was set up to annotate a small number of
posts and the annotation setting was modiﬁed based on the
feedback.
For the second stage of the annotations, terminology associa-
tion, the following guidelines were used. Details are explained in
Section 4.3.
SNOMED CT (SCT) Any span of text annotated with any tag other
than Drug should be mapped to the
corresponding SNOMED CT concept from the
Clinical Finding hierarchy. If no concept exists
then assign the tag concept_less.
AMT Any span of text annotated with Drug should
be mapped to the corresponding AMT concept.
If no matching concept exists then assign the
tag concept_less.
MedDRA Any span of text annotated with ADR should be
mapped to the corresponding MedDRA term.
4.2. Entity identiﬁcation
The ﬁrst stage of the annotation process was identifying men-
tions of the entities of interest, e.g., adverse reactions, in the forum
posts. We used Brat—a web-based text annotation tool developed
in the University of Tokyo [28]—to set up the annotations for this
stage.
Forum posts on the drugs in the Diclofenac category were anno-
tated by four medical students. A 22% fraction of the Lipitor posts
were annotated by the medical students and the rest by two com-
puter scientists. Three of the authors screened the annotations and
corrected clear mistakes. For example, if the annotators had missed
parts of a word (pai instead of pain) during annotation, we ﬁxed
the span. All these annotations were further reviewed by a clinical
terminologist during the normalisation stage.
Fig. 1 shows examples of annotations using Brat. These exam-
ples show the language diversity of how different patients express
their conditions. In example (a), Trazodone is misspelled as
S. Karimi et al. / Journal of Biomedical Informatics 55 (2015) 73–81 77Trazadone by the patient. Also there were two drug tags thyroid
and testostrone (misspelled as testonrone) which were not drug
names and should not have been annotated. Such cases were ﬁxed
in the reviews of the tags. Example (b) contains a colloquial term
charley horse for painful spasms or cramps. It also is a complicated
case of annotation where there are multiple discontinuous tags
that share a common term. Example (c) shows a post written in
all capital letters, where a list of adverse events are given without
any punctuations in between. These examples emphasise the
necessity of development of language processing techniques that
are both capable of handling irregular and colloquial text, and han-
dling medical concepts in such data.
The forum posts were divided evenly between the annotators,
except for 55 documents that were given to all the annotators for
the purpose of calculating the inter-annotator agreement. Two
metrics were used for this calculation: strict agreement and relaxed
agreement, as described by Metke-Jimenez et al. [22]. Both of these
metrics are based on the average of the pair-wise agreement
between the annotators as
agreementði; jÞ ¼ matchðAi;Aj;a; bÞ
maxðnAi ;nAj Þ
;
where Ai represents the set of annotations by annotator i;Aj repre-
sents the set of annotations by annotator j; nAi is the size of set Ai
and nAj is the size of set Aj.matchðAi;Aj;a; bÞ is a function that counts
the number of matching tags. The match function has two binary
parameters: span strictness a and tag strictness b. Both these
parameters can be either strict or relaxed. If span matching is strict,
then the annotations being compared must match exactly. Consider
the sentence ‘‘I experienced increased muscle tension’’. If one
annotator annotates the text fragment ‘‘muscle tension’’ and
another annotates the text fragment ‘‘increased muscle tension’’
then the match function with strict span matching will return no
matches. If span matching is conﬁgured to be relaxed, then
annotations that overlap will be counted as a match, with the
restriction that each annotation can only be matched to one other
annotation. For tag strictness, if both annotators annotate the same
text fragment, for example ‘‘muscle tension’’, but one of them uses
the tag ADR, and the other one uses the tag Symptom, then the
function will return a valid match only if the tag strictness is
relaxed.
Table 4 shows the inter-annotator agreement using different
conﬁgurations of the agreement metric. When span and annotation
settings were both relaxed, the average agreement for Diclofenac
was approximately 78% and for Lipitor it was 95%. Note that agree-
ments are for four annotators for Diclofenac and two for Lipitor.
Therefore, we cannot directly compare these agreements among
the two drugs.8 http://www.meddra.org/.4.3. Terminology association
While annotating entities in a text corpus is valuable in itself,
linking these entities to standard terminologies provides another
level of information on the corpus. Such a process is referred to
as normalisation by other researchers, e.g., Pradhan et al. [25]. An
example of such mapping in the corpora reviewed in Section 2 is
Arizona Disease Corpus [17] in which disease names are mapped
to their corresponding UMLS concepts.
To normalise the CADEC entities, a clinical terminologist
reviewed the entities identiﬁed in the previous stage to map them
to their representative concept in SNOMED CT, AMT, and MedDRA.
During this process the entities that may have been wrongly anno-
tated, were corrected.4.3.1. Linking to SNOMED CT
SNOMED CT (Systematized Nomenclature of Medicine–Clinical
Terms) is a clinical terminology that provides codes, synonyms
and deﬁnitions of clinical terms, and can be accessed through the
UMLS Metathesaurus.
The main beneﬁt of using a standard vocabulary to normalise
the terminology used in the forums is bridging the gap between
the language of lay people and medical experts. It has been argued
that coding clinical documents, such as clinical records, with
SNOMED beneﬁts statistical data collection by providing unam-
biguous, formal, standard terms describing clinically important
information [29]. We therefore chose SNOMED CT as the target
controlled vocabulary to map the entities.
The entities were classiﬁed into the following categories: ADR,
Drug, Disease, Finding, and Symptom. All entities from each cate-
gory with the exception of Drug were mapped to SNOMED CT-AU
(SCT-AU) v20140531 by a clinical terminologist utilising the
CSIRO Snapper tool [23]. Most entities were mapped in a one to
one manner; however, a one to many mapping approach was
undertaken in situations where the entity could be best described
utilising more than one SCT concept. For example the entity ‘‘sev-
ere back pain’’ was mapped to the SCT-AU concepts 76948002
(Severe pain) and 161891005 (Backache). Table 5 lists some exam-
ples from the CADEC entities (last column, Original Entity) mapped
to one or more concept(s) in SNOMED CT.4.3.2. Linking to AMT
The Australian Medicines Terminology (AMT), developed and
maintained by NeHTA Australia, is a terminology designed to
describe and unambiguously identify medicines available in the
Australian healthcare. Its intended use is speciﬁcally within soft-
ware applications utilised in Australian healthcare environments.
Only products registered with the TGA for the purposes of treating
patients are deﬁned within the AMT [24].
The entities from the Drug category were mapped to AMT V2.56
in a one to one manner. For the most part, drugs were mapped to
trade product as mostly they were described in the text entries by
their trade name. However, due to the international nature of the
collection, some drugs which are readily available in the other
countries are not available in Australia. For example, Advicor
which is a combination of Niacin and Lovastatin is not present in
AMT in either trade version or generic product so was therefore
assigned the value concept_less. If drugs could not be found within
the AMT utilising the trade name the generic form of the drug was
then searched and if present utilised as the equivalent map. For
example the drug Aciphex was mapped to its generic form
21296011000036107 (Rabeprazole) or the drug Cataﬂam was
mapped to 21288011000036105 (Diclofenac). AMT is not struc-
tured to include concepts for drug classes so entities that were
described as antibiotics or statins, for example, were assigned the
value concept_less. Some drugs were too ambiguous to assign a
concept from AMT, such as benadryl; AMT contains many versions
of benadryl so it was not possible to deﬁnitively assign a mapping.
Table 5 shows the mappings assigned to Cataﬂam and Demerol.4.3.3. Linking to MedDRA
MedDRA8 (Medical Dictionary for Regulatory Activities) is the
standard thesaurus used by the pharmaceutical industry and reg-
ulatory agencies such as the FDA. It contains vocabulary used for
adverse drug reactions structured in a hierarchy. The Lowest Level
Term (LLT) is the most speciﬁc terminology that expresses an
individuals condition such as ‘‘feeling queasy’’. One level up is
Preferred Terms (PT), which together with LLTs are often used in
(a) Drug Trazodone misspelled
(b) Multiple discontinious tags overlapping
(c) All capital letters and no punctuation used
Fig. 1. Examples of entity annotation. (a) An example of drug misspellings; (b) An example of complicated annotations; and (c) An example of irregular text.
Table 4
Average pair-wise agreement (percentage) between annotators.
Span a Tag b Agreement
Diclofenac Lipitor
Strict Strict 46.6 74.2
Strict Relaxed 49.1 81.6
Relaxed Strict 68.7 85.1
Relaxed Relaxed 77.9 94.8
Table 5
SNOMED CT and AMT normalisation examples.
SCT code Concept Original entity
76948002 Severe pain Extreme pain in both shoulders
45326000 Shoulder pain
284140004 Unable to move
arm
Unable to reach the top of my
head with my hands
70733008 Limitation of
joint movement
Movement is restricted and it is
impossible to make a ﬁst
76948002 Severe pain Extreme pain
271599002 Feeling content Mellows me out
68962001 Myalgia Muscle pain
AMT code
21288011000036105 Diclofenac Cataﬂam
34839011000036106 Pethidine Demerol
concept_less – Felt much older than I was
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and regulators. Upper levels in MedDRA hierarchy are more generic.
We used MedDRA V16.0 to annotate the concepts identiﬁed in
the SNOMED CT mapping stage. These concepts were annotated
at the LLT level, to capture the speciﬁc terms that express the
patients’ conditions. Table 6 shows examples of MedDRA normal-
isations from the CADEC corpus. The last column, Original Entity,
is the entity identiﬁed in the ﬁrst stage of annotation, and the ﬁrst
column is the corresponding MedDRA concept identiﬁer. We list
other information that can be retrieved from MedDRA given the
MedDRA ID regarding that entity in the second and third columns.
The second to last row is an example of one entity being mapped to
two MedDRA IDs.
If an entity was mapped to more than one SCT concept, all the
SCT concepts were then mapped to MedDRA. For example ‘‘severe
back pain’’ which was mapped to two SCT concepts Severe pain
and Backache, these concepts were then mapped to the MedDRA
LLT concepts 10003993 (Backache) and 10033371 (Pain).
However, it should be noted that in this particular case due to
the classiﬁcatory nature of MedDRA the second map is superﬂuous
as it does not add further deﬁnition.
4.3.4. Normalisation challenges
While mapping of free text entries such as these certainly gives
an added layer to the knowledge bank, it can occasionally be some-
what subjective. Pain is a good example of such subjectivity. An
entity such as ‘‘pain so bad I thought I was going to die’’, can be
coded either as severe pain or excruciating pain. In terms of
Table 6
MedDRA normalisation examples.
MedDRA ID Preferred
name
Classiﬁed as Original entity
10040617 Shoulder
pain
Musculoskeletal
pain
Extreme pain in both
shoulders
10033407 Pain
hunger
Abdominal pain
upper
Hunger pangs
10038742 Restless
legs
Restless legs
syndrome
Legs are restless
10043890 Tiredness Fatigue Very tired
10069830 Unable to
eat
Aphagia Couldn’t eat or drink
10069830 Unable to
eat
Aphagia Can’t eat normal
10013781 Dry mouth 9 classes, e.g., Oral
dryness
Dry mouth
10003068 Aptyalism 4 classes, e.g., Asialia
concept_less – – Lungs feel heavy
Table 7
Number of entities annotated in the entire corpus and each of the drug categories, as
well as the unique number of entities per each category.
Entity Corpus Diclofenac Lipitor
All Unique All Unique All Unique
ADR 6318 2713 888 508 5445 2316
Disease 283 162 59 42 226 129
Drug 1800 321 246 113 1542 222
Symptom 275 130 239 103 38 30
Finding 435 265 41 34 394 238
All 9111 3591 1473 800 7645 2935
Table 8
Number of continuous and discontinuous tags of each type.
ADRs Diseases Symptoms Findings Drugs All
Continuous 5318 280 255 397 1797 8047
Discontinuous 918 2 13 34 2 969
(overlapping)
Discontinuous 82 1 7 4 1 95
(non-overlapping)
Total 6318 283 275 435 1800 9111
Table 9
Most frequent entity values for each of the drug categories with their frequencies in
brackets.
Entity Top 5 for Diclofenac Top 5 for Lipitor
ADR Diarrhea (28), nausea (25),
vaginal bleeding (17), cramps
(16), dizziness (14)
Pain (185), fatigue (84),
depression (83), muscle pain
(82), memory loss (62)
Disease Arthritis (10), endometriosis (3),
migraines (2), bi-polar (2),
plantar fasciitis (2), ibs (2), post
traumaic osteoarthritis (1),
lower lumbar arthritis (1)
Heart attack (14), arthritis
(13), diabetes (8),
ﬁbromyalgia (8), ms (6)
Drug Arthrotec (53), voltaren (25),
celebrex (9), cataﬂam (6), advil
Lipitor (1034), zocor (44),
pravachol (22), crestor (20),
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ity is not such an issue as MedDRA being classiﬁcatory in nature,
is only interested in the pain. Other examples such as ‘‘I couldn’t
get out of bed’’ were assigned a concept_less value due to the uncer-
tainty of what the person was trying to convey. It is unclear if they
meant ‘‘I am so tired I can’t get out of bed’’ or ‘‘I didn’t feel like get-
ting out of bed’’ or ‘‘I am physically incapable of getting out of bed
due to physical impairments’’. The SCT concept which refers to
‘‘getting out of bed’’ is utilised to describe a person’s physical abil-
ity to ‘‘get out of/or off the bed’’, i.e. if these persons are able to sit
up by themselves, swing their legs to the side and get to a standing
position. MedDRA, however, does not have a term for ‘‘unable to
get out of bed’’.
There were some entities that were parsed such that they
missed subtle context. For example ‘‘Memory loss/ability to con-
centrate’’ was parsed as ‘‘memory loss’’ and ‘‘ability to concen-
trate’’. However it is more likely that the entry was meant to
convey ‘‘memory loss’’ and ‘‘loss of ability to concentrate’’ hence
the latter was mapped to a concept equivalent of ‘‘loss of ability
to concentrate’’.(6), ibuprofen (6), aleve (5) coq10 (19)
Finding Stroke (2), menopause (2), heart
attack (2), stomach trouble (1),
arthritis (1)
Arthritis (17), high cholesterol
(15), heart attack (13), stress
(8), pain (7)
Symptom Pain (89), knee pain (8), back
pain (6), inﬂammation (4),
agony (3), lower back pain (3)
Pain (3), inﬂamation (2),
menopause (2), low bp and
pulse (1), anxiety (1)5. Corpus statistics
In the ﬁrst stage of the annotation, 64 posts (5.1%) did not
receive any entity annotation and therefore did not require nor-
malisation. After the normalisation stage, a further 78 posts (total
of 142 posts or 11.4%) received no MedDRA annotations. An exam-
ple of a post that did not receive any entity annotation was a post
on Lipitor with the content: I did not experience any of the myriad of
possible side effects of the drug.
We created a consolidated corpus in which for the portion of
the corpus that received multiple annotations, only one set based
on random choice of an annotator, was used for calculating the
statistics. A better solution for a corpus that is annotated by multi-
ple annotators would have been following the centroid method by
Lewin et al. [20].
Table 7 lists the frequency of the annotated entities in the entire
corpus as well as in each drug category (Lipitor and Diclofenac)
separately. A total of 9111 entities were identiﬁed. ADRs comprised
69.3% of the total number of entities, followed by drugs (1800 or
19.8%). From all the 9111 annotated entities, only 39.4% (3591 enti-
ties) were unique; people generally reported similar reactions.
The number of entities annotated as Symptom was larger for
Diclofenac than Lipitor (239 compared to 38) even though the
number of Diclofenac posts was much smaller. The reason being,
often patients mentioned pain as their symptom or the reason for
taking the medication, whereas for Lipitor/Atorvastatin thesymptoms related to Hypercholesterolemia (high cholesterol) were
not mentioned in the posts as often.
Table 8 reports the number of continuous and discontinuous
tags that were annotated during the entity annotation step.
Continuous tags represent a continuous set of words, where as dis-
continuous tags are broken into multiple spans within a sentence.
Examples of such discontinuous tags are shown in Fig. 1 (b).
We then looked at the entities that were annotated with any of
the labels. Table 9 lists the most frequent entity values for each of
the ﬁve types of entities (Drug, ADR, Disease, Symptom, and
Finding) for the two drug categories. Given the two drug categories
in the corpus treat very different conditions, their entity values for
almost all the entity categories were different as well. For example,
therewasa cleardistinctionbetween the setsof drugsmentioned for
Diclofenac and Lipitor. However, the drugs mentioned in the posts
were often alternative or complementary drugs taken by the
patients, and they rarely mentioned other medications that they
were taking while on the drug that was the subject of their post.
Annotations from the normalisation stage were also analysed
with statistics shown in Table 10. The ﬁnal set contained 1655 con-
cepts from AMT, from which only 123 (7.4%) were unique. In other
Table 10
Statistics on entities normalised with AMT, SNOMED CT (SCT) and MedDRA.
AMT SCT MedDRA
No. annotated concepts 1655 7259 6569
No. unique concepts 123 924 686
Mean per post 1.2 5.4 5.2
Maximum no. concepts per
post
17 42 34
1st most freq. concept Lipitor
(1073)
Pain (371) Pain (485)
2nd most freq. concept Arthrotec
(62)
Myalgia (288) Myalgia
(311)
3rd most freq. concept Zocor (48) Severe pain
(196)
Arthralgia
(311)
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all the posts. On average, there was 1.2 drug name concepts per
post linked to AMT. In an extreme case, we had a post with 14 drug
brand names which linked to AMT. Similar statistics are reported
for SCT and MedDRA in Table 10. We also report the three most fre-
quently linked concepts together with their frequencies across the
corpus for each terminology at the bottom of Table 10.
6. Lessons learnt
In the process of creating the CADEC corpus, a number of deci-
sions were made with regard to what should be annotated, rules
associated with this and the tools best suited to the completion
of the exercise. The main web-based tool used was Brat. It provided
a number of advantages: creating character offset based annota-
tions in plain text ﬁles that were easy to process, as well as an easy
to set up and annotate interface. However, one shortcoming of this
tool was automatic provision of a default tag in case an annotator
highlights a fraction of the text but forgets to select the suitable
tag. In our case, Brat had chosen the tag Drug for such cases. We
therefore introduced an additional step to review the annotations
and modify the incorrect tags.
7. CADEC limitations
CADEC imposes the following limitations that could affect the
studies that use this dataset:
Data type Social media text is often noisy and contains inaccu-
rate, incomplete, or even false information.
Data source There are likely limitations inherited from our data
source: AskaPatient. There might be a speciﬁc group
of consumers that use AskaPatient to review their
medications. There might also be implications inher-
ited from the data structure used in AskaPatient to
collect the reviews.
Data size The size of the corpus, 1253 posts, is limited which is
not representative of all the drugs and consumer
reviews existing on the web.
Limited coverage of drug types and adverse effects CADEC only
includes drugs that contained Diclofenac and
Atorvastatin in their active ingredients. Therefore,
the range of adverse events in the corpus are those
of 12 drugs that are present in the corpus, and
adverse effects speciﬁc to other drug types are
absent. Even for the drugs covered in the dataset,
the coverage of rare adverse events known as,
idiosyncratic drug reactions,9 is limited.9 Idiosyncratic drug reactions are also known as Type B side-effects and are seen
very rarely among individuals that their immune system react to certain medications
even in small dosage.Lack of drug–drug interactions and drug overdose annotations The
information provided in the reports by the consumers
are often focused on one speciﬁc medication.
Therefore, information on other drugs that are
administered by the consumers are often missing.
This causes lack of information on potential drug-drug
interactions that have caused the reported adverse
reactions. The same applies for the dosage and
frequency of medication usage. Whether the patient
has experienced adverse effects due to overdose or
not is not known due to the nature of these reports.
We have not annotated the corpus for drug-drug
interactions or intoxication due to overdose.
Annotator errors Despite our efforts for precise annotations, the
dataset may contain human errors in identifying the
concepts or linking them to the medical terminologies.
Annotation errors will affect the evaluation of any
automated system that uses CADEC as gold standard.
8. Conclusions and future work
We created an open access corpus named CADEC (CSIRO Adverse
Drug Event Corpus) for researchers of text mining for
pharmacovigilance. The corpus is composed of medication con-
sumer posts from a medical forum, AskaPatient, annotated with
concepts such as drug names, adverse reactions, diseases, and
symptoms. These concepts are linked to their corresponding con-
cepts in controlled vocabularies. The CADEC corpus provides
opportunities for researchers in a number of areas to (1) develop
and evaluate systems that automatically extract adverse drug
events from layperson reports; (2) develop systems that extract
medications from free-text; (3) develop systems that automatically
map free-text to SNOMED CT or MedDRA, because it contains a rich
mapping of informal terminology to formal, as expressed in
SNOMED CT and MedDRA; and (4) employ variants in expressing
onemedical condition by laypeople, or spellings of drug names, that
are captured in CADEC, in addition to the Consumer Health
Vocabulary (CHV) in dictionary-based text mining algorithms.
The challenges of annotating data from medical forums which
comprise irregular text and colloquial language were also dis-
cussed. Most notably, in such data, text spans are often ambiguous,
creating challenges for standard text processing techniques.
We are in the process of annotating the corpus with relation-
ships as well as including other entities such as medication dosage
and frequency.
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